# A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

> **NCT06761677** · PHASE1,PHASE2 · SUSPENDED · sponsor: **SymBio Pharmaceuticals** · enrollment: 43 (estimated)

## Conditions studied

- Relapsed or Refractory Lymphoma Including ENKL

## Interventions

- **DRUG:** Brincidofovir

## Key facts

- **NCT ID:** NCT06761677
- **Lead sponsor:** SymBio Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-06-09
- **Primary completion:** 2027-10-23
- **Final completion:** 2029-05-08
- **Target enrollment:** 43 (ESTIMATED)
- **Why stopped:** Due to challenges in recruiting eligible patients under the protocol.
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06761677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06761677, "A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06761677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*